These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 19747013

  • 1. Liraglutide: a review of its use in type 2 diabetes mellitus.
    Croom KF, McCormack PL.
    Drugs; 2009 Oct 01; 69(14):1985-2004. PubMed ID: 19747013
    [Abstract] [Full Text] [Related]

  • 2. Liraglutide: a review of its use in the management of type 2 diabetes mellitus.
    Perry CM.
    Drugs; 2011 Dec 03; 71(17):2347-73. PubMed ID: 22085389
    [Abstract] [Full Text] [Related]

  • 3. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov 03; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 4. Liraglutide: from clinical trials to clinical practice.
    Gough SC.
    Diabetes Obes Metab; 2012 Apr 03; 14 Suppl 2():33-40. PubMed ID: 22405267
    [Abstract] [Full Text] [Related]

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Apr 03; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 6. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R, Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.
    Diabetologia; 2009 Oct 03; 52(10):2046-55. PubMed ID: 19688338
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR.
    Diabetes Obes Metab; 2013 Mar 03; 15(3):204-12. PubMed ID: 22985213
    [Abstract] [Full Text] [Related]

  • 11. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
    Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S, LEAD-1 SU study group.
    Diabet Med; 2009 Mar 03; 26(3):268-78. PubMed ID: 19317822
    [Abstract] [Full Text] [Related]

  • 12. Liraglutide in type 2 diabetes mellitus.
    Baruah MP, Chaudhury T, Sethi BK, Dharmalingam M.
    J Indian Med Assoc; 2012 May 03; 110(5):335-8. PubMed ID: 23360033
    [Abstract] [Full Text] [Related]

  • 13. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr 05; 52(1335):25-7. PubMed ID: 20360660
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).
    Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M.
    Diabetes Obes Metab; 2011 Jan 05; 13(1):81-8. PubMed ID: 21114607
    [Abstract] [Full Text] [Related]

  • 17. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.
    Blonde L, Russell-Jones D.
    Diabetes Obes Metab; 2009 Dec 05; 11 Suppl 3():26-34. PubMed ID: 19878259
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Is liraglutide a useful addition to diabetes therapy?
    Mikhail NE.
    Endocr Pract; 2010 Dec 05; 16(6):1028-37. PubMed ID: 20439238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.